News | December 30, 2025
Astal signs LoI with Immuna Therapeutics
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
The companies aim to expand treatment options for millions living with metabolic disorders
Akero became a wholly owned subsidiary of Novo Nordisk
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
Subscribe To Our Newsletter & Stay Updated
